Plain-English translation of NCT04790305 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a natural supplement called can improve survival and reduce cancer recurrence when taken alongside standard cancer treatment for early-stage triple-negative breast cancer. Triple-negative breast cancer is an aggressive type that accounts for about 10–20% of all breast cancers and tends to come back more often than other types. Researchers hope this medication might help prevent the cancer from returning and improve long-term survival.
Current standard treatments don't work well enough to prevent early-stage triple-negative breast cancer from coming back in many patients. Early studies suggest this medication may help lower recurrence risk and improve survival, so researchers want to test whether it truly works in a large group of patients.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to either take the supplement three times daily alongside your regular cancer treatment, or to receive standard care alone. You'll visit the clinic every 3 months for the first 2 years while receiving treatment, and then every 6 months for 3 years afterward. The entire study lasts 5 years, with doctors checking for any signs of cancer returning and monitoring your overall health throughout.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China